Related Experiment Videos
Interventions in acute myocardial infarction
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
Insights
Urgent coronary revascularization benefits acute myocardial infarction patients. Intravenous thrombolytic therapy is preferred for younger patients within 6 hours, while optimal reperfusion strategies require further research.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute myocardial infarction (MI) necessitates urgent treatment.
- Intravenous thrombolytic therapy is a primary treatment for eligible MI patients.
- Timeliness of treatment significantly impacts outcomes.
Purpose of the Study:
- To review the benefits of urgent coronary revascularization in acute MI.
- To evaluate current and emerging thrombolytic agents and strategies.
- To identify areas for further research in reperfusion therapy.
Main Methods:
- Review of multiple studies on acute myocardial infarction treatment.
- Analysis of intravenous thrombolytic therapies, including streptokinase, urokinase, and tissue-type plasminogen activator (t-PA).
- Evaluation of adjunctive therapies like angioplasty and bypass surgery.
Main Results:
- Urgent revascularization is proven beneficial for acute MI.
- Thrombolytic therapy is effective for patients within 6 hours of symptom onset.
- Tissue-type plasminogen activator (t-PA) shows potential advantages in clot selectivity and time-independent efficacy.
- Optimal thrombolytic combinations and the role of angioplasty/bypass surgery in specific scenarios require further investigation.
Conclusions:
- Coronary revascularization is crucial for acute MI management.
- Thrombolytic therapy remains a cornerstone, with ongoing evaluation of agents like t-PA.
- Further research is essential to optimize reperfusion strategies and improve patient survival.
Abstract:
Results of multiple studies have amply verified the benefit of urgent coronary revascularization for patients who have acute myocardial infarction (MI). Currently, intravenous thrombolytic therapy is the treatment of choice for many patients, especially those 75 years old or younger who present within 6 hours of symptom onset and who are without contraindications to thrombolytic therapy. Some patients treated within 6-24 hours of symptom onset may also benefit, but this remains unproven. The thrombolytic agents currently in use or being extensively evaluated include streptokinase, urokinase, tissue-type plasminogen activator (t-PA), anisoylated plasminogen streptokinase activator complex (APSAC or anistreplase), and single-chain urokinase-type plasminogen activator (scu-PA). The agent t-PA has the potential advantage of being clot selective and, thereby, relatively fibrinogen sparing, and its efficacy in terms of restoration of vessel patency is less dependent on the time of administration as compared with that of streptokinase and urokinase. It is not yet known whether this will translate into improved patient survival as compared with that achieved by the less-expensive agents streptokinase and APSAC. Treatment regimens of combination thrombolytic agents have been developed, but the optimal combinations have not yet been determined. Patients who are in cardiogenic shock and those in whom thrombolytic therapy is contraindicated can probably benefit from angioplasty or bypass surgery. Results of several studies have suggested that immediate angioplasty after successful thrombolysis is not beneficial; however, the potential benefit of angioplasty or bypass surgery for failed thrombolytic therapy is yet to be evaluated. Although many advances have been made, further research is clearly needed in the area of reperfusion.